Abcellera Biologics Inc (ABCL)vsJohnson & Johnson (JNJ)
ABCL
Abcellera Biologics Inc
$12.65
-0.08%
HEALTHCARE · Cap: $3.39B
JNJ
Johnson & Johnson
$269.29
-0.10%
HEALTHCARE · Cap: $640.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 147896% more annual revenue ($97.93B vs $66.17M). JNJ leads profitability with a 21.5% profit margin vs -248.8%. JNJ earns a higher WallStSmart Score of 59/100 (C).
ABCL
Avoid27
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.4%
Fair Value
$6.87
Current Price
$12.65
$5.78 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 45.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Distress zone — elevated risk
ROE of -15.3% — below average capital efficiency
Revenue declined 76.3%
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Debt/Equity, EPS Growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : ABCL
The primary concerns for ABCL are Altman Z-Score, Return on Equity, Revenue Growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ABCL profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.32 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 27/100), backed by strong 21.5% margins. ABCL offers better value entry with a 54.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?